BioCentury | Oct 2, 2020
Deals

Genentech neoantigen deal gives Vaccibody runway to speed up infectious disease pipeline

...million in upfront and near-term payments, Norwegian biotech Vaccibody...
...to VB10.NEO, a personalized DNA-based neoantigen vaccine. Vaccibody...
...million in milestones plus tiered, low double-digit royalties.Vaccibody...
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...added three members to its Entrepreneur-in-Residence program: Martin Bonde, who stepped down as CEO of Vaccibody A/S...
BioCentury | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

...Cancer (SITC) meeting in National Harbor, Md. Vaccibody's neoantigen cancer vaccine leads to 50% ORR Vaccibody A/S...
...The preliminary data also showed the personalized neoantigen cancer vaccine was well tolerated. This half, Vaccibody...
...Writer Opdivo (Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Vaccibody A/S Celyad...
BioCentury | Aug 7, 2017
Company News

Management tracks: Pfenex, Alvotech, uniQure

...was COO at Tobira Therapeutics Inc. , now part of Allergan plc (NYSE:AGN). Vaccine company Vaccibody A/S...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

...Adenoviral DNA vector encoding over 100 neoantigens Cancer Preclinical Unknown Life Sciences Partners; Versant Ventures Vaccibody A/S...
BioCentury | Dec 16, 2016
Financial News

Vaccibody raises NOK220M in private placement

...Vaccine company Vaccibody A/S (Oslo, Norway) raised NOK220 million ($26 million) through the sale of 880,000 shares...
...sale of 880,000 shares at NOK250 in a private placement with new and existing investors. Vaccibody...
...malignancies. Capital has become increasingly available for start-ups in Scandinavia (see BioCentury, Aug. 22) . Chris Lieu VB10.16 Vaccibody A/S...
BioCentury | Dec 16, 2016
Financial News

Vaccibody completes private placement

...$26 million) in a venture round with new and existing investors. Vaccibody A/S , Oslo, Norway Alicia Parker Vaccibody A/S...
BioCentury | Sep 5, 2016
Clinical News

VB10: Interim Phase I/IIa data

...14 evaluable patients, 12 patients (86%) achieved “strong induction” of HPV16-specific T cell immune responses. Vaccibody...
...patients (75%) regressed to CIN grade 1 or no disease at 6 months of follow-up. Vaccibody...
...of the trial to the expansion Phase IIa portion, which will enroll 15-20 additional patients. Vaccibody A/S...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

...ventures business from other industries but certainly weren't biotech specialists," said Martin Bonde, CEO of Vaccibody A/S...
...Rock or a Versant that does things in a big way from the beginning," said Vaccibody's...
...York, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Tekes, Helsinki, Finland Umeå University , Umeå, Sweden Vaccibody A/S...
BioCentury | Mar 14, 2016
Clinical News

VB10: Completed Phase I/IIa enrollment

...selected from the first part in 15-20 patients with CIN grade 2 or 3 lesions. Vaccibody A/S...
Items per page:
1 - 10 of 15
BioCentury | Oct 2, 2020
Deals

Genentech neoantigen deal gives Vaccibody runway to speed up infectious disease pipeline

...million in upfront and near-term payments, Norwegian biotech Vaccibody...
...to VB10.NEO, a personalized DNA-based neoantigen vaccine. Vaccibody...
...million in milestones plus tiered, low double-digit royalties.Vaccibody...
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...added three members to its Entrepreneur-in-Residence program: Martin Bonde, who stepped down as CEO of Vaccibody A/S...
BioCentury | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

...Cancer (SITC) meeting in National Harbor, Md. Vaccibody's neoantigen cancer vaccine leads to 50% ORR Vaccibody A/S...
...The preliminary data also showed the personalized neoantigen cancer vaccine was well tolerated. This half, Vaccibody...
...Writer Opdivo (Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Vaccibody A/S Celyad...
BioCentury | Aug 7, 2017
Company News

Management tracks: Pfenex, Alvotech, uniQure

...was COO at Tobira Therapeutics Inc. , now part of Allergan plc (NYSE:AGN). Vaccine company Vaccibody A/S...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

...Adenoviral DNA vector encoding over 100 neoantigens Cancer Preclinical Unknown Life Sciences Partners; Versant Ventures Vaccibody A/S...
BioCentury | Dec 16, 2016
Financial News

Vaccibody raises NOK220M in private placement

...Vaccine company Vaccibody A/S (Oslo, Norway) raised NOK220 million ($26 million) through the sale of 880,000 shares...
...sale of 880,000 shares at NOK250 in a private placement with new and existing investors. Vaccibody...
...malignancies. Capital has become increasingly available for start-ups in Scandinavia (see BioCentury, Aug. 22) . Chris Lieu VB10.16 Vaccibody A/S...
BioCentury | Dec 16, 2016
Financial News

Vaccibody completes private placement

...$26 million) in a venture round with new and existing investors. Vaccibody A/S , Oslo, Norway Alicia Parker Vaccibody A/S...
BioCentury | Sep 5, 2016
Clinical News

VB10: Interim Phase I/IIa data

...14 evaluable patients, 12 patients (86%) achieved “strong induction” of HPV16-specific T cell immune responses. Vaccibody...
...patients (75%) regressed to CIN grade 1 or no disease at 6 months of follow-up. Vaccibody...
...of the trial to the expansion Phase IIa portion, which will enroll 15-20 additional patients. Vaccibody A/S...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

...ventures business from other industries but certainly weren't biotech specialists," said Martin Bonde, CEO of Vaccibody A/S...
...Rock or a Versant that does things in a big way from the beginning," said Vaccibody's...
...York, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Tekes, Helsinki, Finland Umeå University , Umeå, Sweden Vaccibody A/S...
BioCentury | Mar 14, 2016
Clinical News

VB10: Completed Phase I/IIa enrollment

...selected from the first part in 15-20 patients with CIN grade 2 or 3 lesions. Vaccibody A/S...
Items per page:
1 - 10 of 15